

Driscoll Health Plan Medical Necessity Guideline

| | | | |
|--|---|---------------------------------------|--|
| Medical Necessity Guideline: Cystic Fibrosis Carrier Screening-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) | Creation Date: 09/24/2018 | Review Date: 05/29/2025 | Effective Date: 07/17/2025 |
|--|---|---------------------------------------|--|

PURPOSE:

To define the requirements and documentation for Cystic Fibrosis Carrier Screening (CPT codes 81220; 81221; 81222, and 81223).

LINE OF BUSINESS: STAR, STAR Kids, and CHIP

DEFINITIONS:

Cystic Fibrosis Carrier Screening - genetic testing that determines whether an asymptomatic person has a genetic mutation or abnormalities associated with this particular disorder that may be passed on to children. The cause is related to a defect in the gene that produces a protein called cystic fibrosis transmembrane conductance regulator (CFTR). The most common defect is F508 which is approximately 70% of the > 1000 possible mutations. The current screen is limited to this one defect. As a result, about 30% of carrier states are missed. Extended CFTR panels are now available.

Cystic Fibrosis - a hereditary disorder affecting the exocrine glands. It causes the production of abnormally thick mucus, leading to the blockage of the pancreatic ducts, intestines, and bronchi and often resulting in respiratory infection. It affects about one out of every 3,000 newborns. About one in 25 people is a carrier. ^(1, 2)

GUIDELINE:

Driscoll Health Plan (DHP) requires prior authorization of all requests for Cystic Fibrosis Carrier Screening (CPT codes 81220; 81221; 81222, and 81223). This requirement includes Obstetricians/Gynecologists, Family Practice physicians and Mid-Level practitioners doing Obstetrics.

Documentation requirements:

DHP requires completion and submission of an “OB ATTESTATION FOR CYSTIC FIBROSIS SCREENING” (ATTACHMENT A).

Confidential: For use only by employees and authorized agents of Driscoll Health Plan. This document contains confidential and proprietary information NOT to be reproduced or distributed to others without the prior written consent of Driscoll Health Plan

Driscoll Health Plan Medical Necessity Guideline



BACKGROUND:

- Cystic fibrosis (CF) carrier screening (CPT 81220, 81221, 81222, and 81223) is a benefit and payable under Texas Medicaid without restrictions.
- The American College of Obstetrics and Gynecology (ACOG) states that Cystic fibrosis carrier screening be offered to all women due to the pan-ethnicity of the general population. Partner screening should be available if the woman tests positive for the carrier state. ⁽¹⁾
- ACOG recommends screening should be offered to couples prior to pregnancy. ⁽¹⁾
- Patients should be availed of genetic counseling before and after the results of testing. In addition, ACOG underscores the importance of carefully reviewing carrier screening results with patients: “Patients must clearly understand what their results mean to feel empowered and enabled to make informed decisions about their reproductive health or prepare to care for future children. In some instances, this may include referring patients to genetic specialists to ensure they receive education and care tailored to their carrier screening results.”
- Cystic Fibrosis Carrier Screening should be limited to once per lifetime. Patients should be advised they have the right to opt-out of genetic screening for this and other conditions. ⁽⁴⁾

PROVIDER CLAIMS CODES:

| CPT | | | |
|-------|-------|-------|-------|
| 81220 | 81221 | 81222 | 81223 |

REFERENCES:

1. ACOG Committee Opinions, “Carrier Screening in the Age of Genomic Medicine,” #690, and “Carrier Screening for Genetic Conditions,” #691, March 2017 issue of *Obstetrics and Gynecology*. Reaffirmed 2020., <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions>; Accessed 04/30/2021
2. US National Library of Medicine, Genetics Home Reference (2020), Cystic Fibrosis; <https://ghr.nlm.nih.gov/condition/cystic-fibrosis>. Accessed 05/14/2021.
3. Texas Medicaid Provider Procedures Manual (current edition): Texas Medicaid Fee Schedule
4. Texas Medicaid Provider Procedures Manual, Medical and Nursing Specialists, Physicians, and Physician Assistants Handbook, Section 5, Geneticists, May 2025.

Confidential: For use only by employees and authorized agents of Driscoll Health Plan. This document contains confidential and proprietary information NOT to be reproduced or distributed to others without the prior written consent of Driscoll Health Plan

Driscoll Health Plan Medical Necessity Guideline

DOCUMENT HISTORY:

| DHP Committee that Approved | <i>Review Approval Date (last 5 years)</i> | | | | |
|-----------------------------------|--|------------|------------|------------|--|
| | | | | | |
| Medical Director | 05/24/2022 | 05/30/2023 | 05/22/2024 | 05/29/2025 | |
| CMO | 06/07/2022 | 06/06/2023 | 06/11/2024 | 06/10/2025 | |
| Medical Policy Workgroup | 06/07/2022 | 06/06/2023 | 06/11/2024 | 06/10/2025 | |
| Utilization Management & Appeals | 06/21/2022 | 06/20/2023 | 06/18/2024 | 06/17/2025 | |
| Provider Advisory Committee (PAC) | 06/17/2022 | 06/09/2023 | 07/01/2024 | 06/24/2025 | |
| Clinical Management & Committee | 06/24/2022 & 08/23/2022 | 07/20/2023 | 07/24/2024 | 07/01/2025 | |
| Executive Quality Committee | 06/28/2022 | 07/25/2023 | 07/30/2024 | 07/17/2025 | |

| <i>Document Owner</i> | <i>Organization</i> | <i>Department</i> |
|------------------------------------|----------------------|------------------------|
| Dr. Fred McCurdy, Medical Director | Driscoll Health Plan | Utilization Management |

| <i>Review/Revision Date</i> | <i>Review/Revision Information, etc.</i> |
|-----------------------------|--|
| 11/19/2018 | No changes |
| 11/04/2019 | Updated TMPPM reference, Review ACOG literature |
| 05/12/2020 | Updated Format, references, ACOG literature is current |
| 06/04/2020 | Updated language per Dr. Serrao |
| 05/14/2021 | Updated references including ACOG and TMPPM |
| 08/02/2021 | Removal of specific laboratories that were named and revised to in network lab |

Confidential: For use only by employees and authorized agents of Driscoll Health Plan. This document contains confidential and proprietary information NOT to be reproduced or distributed to others without the prior written consent of Driscoll Health Plan

Driscoll Health Plan Medical Necessity Guideline



| | |
|---------------------------|--|
| 05/13/2022 | Reviewed, references updated, minor editing revisions by Dr. Fred McCurdy |
| 05/30/2023 | Reviewed by Dr. Fred McCurdy, MD, no changes |
| 03/21/2024 | Attachment A-Cystic Fibrosis Attachment Form updated for formatting and form identifier with no change to content. |
| 05/22/2024 | Reviewed and revised by Drs. Roxanne Doucet and Fred McCurdy |
| 05/13/2025- 05/29/2025 | Annual review and revision initiated 5/13/2025 and completed on 05/29/2025 by Drs. Roxanna Doucet and Dan Doucet |

Attachment A

- Cystic Fibrosis Carrier Screening should be limited to once per lifetime. Patients should be advised they have the right to opt-out of genetic screening for this and other conditions.

Confidential: For use only by employees and authorized agents of Driscoll Health Plan. This document contains confidential and proprietary information NOT to be reproduced or distributed to others without the prior written consent of Driscoll Health Plan

**Cystic Fibrosis Carrier Screening Attestation for OB GYNs**

Driscoll Health Plan (DHP) requires prior authorization of all requests for Cystic Fibrosis Carrier Screening (CPT codes 81220, 81221, 81222, and 81223).

Cystic Fibrosis Carrier Screening is genetic testing that determines whether an asymptomatic person has a genetic mutation or abnormalities associated with this particular disorder that may be passed on to children. The cause is related to a defect in the gene that produces a protein called cystic fibrosis transmembrane conductance regulator (CFTR). The most common defect is F508, which is approximately 70% of the > 1000 possible mutations. The current screen is limited to this one defect. Approximately 30% of carrier states are missed. Extended CFTR panels are now available.

Cystic Fibrosis is a hereditary disorder affecting the exocrine glands. It causes the production of abnormally thick mucus, leading to the blockage of the pancreatic ducts, intestines, and bronchi and often resulting in respiratory infection. It affects about one out of every 3,000 newborns.

About one in 25 people is a carrier.

DHP Guideline:

- Cystic fibrosis (CF) carrier screening (CPT 81220, 81221, 81222, and 81223) is a benefit and payable under Texas Medicaid without restrictions.
- The American College of Obstetrics and Gynecology (ACOG) states that Cystic fibrosis carrier screening should be offered to all women due to the pan-ethnicity of the general population. In addition, partner screening should be available if the woman tests positive for the carrier state.
- ACOG recommends screening should be offered to couples prior to pregnancy.
- Patients should be availed of genetic counseling prior to and after the results of testing. In addition, ACOG underscores the importance of carefully reviewing carrier-screening results with patients: "Patients must clearly understand what their results mean to feel empowered and enabled to make informed decisions about their

Confidential: For use only by employees and authorized agents of Driscoll Health Plan. This document contains confidential and proprietary information NOT to be reproduced or distributed to others without the prior written consent of Driscoll Health Plan

Driscoll Health Plan Medical Necessity Guideline



reproductive health or prepare to care for future children. In some instances, this may include referring patients to genetic specialists to ensure they receive education and care tailored to their carrier screening results.”

- Cystic Fibrosis Carrier Screening should be limited to once per lifetime. Patients should be advised they have the right to opt out of genetic screening for this and other conditions.

Member Name: _____

Member DOB: _____

Member ID: _____

DHP requires the ordering physician to attest to all of the following for CF carrier screening:

- ☐ To the best of the provider’s knowledge, the member has not had Cystic Fibrosis carrier screening before this request.
- ☐ Member has received counseling on genetic screening and informed of his/her ability to opt- out of any and all screening.
- ☐ The provider has the expertise in or timely accessibility to genetic counseling for a member with positive screens.
- ☐ If not performed by an in-network lab, there is medical necessity, unavailability, or other impediments to access to justify referral to another laboratory.

PHYSICIAN SIGNATURE

DATE

PHYSICIAN NAME (PRINT)

PROV-UM-009 02/2024

4525 Ayers Street
Corpus Christi, Texas 78401
Phone: 1-877-455-1053 Fax: 1-866-741-5650

Confidential: For use only by employees and authorized agents of Driscoll Health Plan. This document contains confidential and proprietary information NOT to be reproduced or distributed to others without the prior written consent of Driscoll Health Plan